INSULIN GLARGINE (LANTUS) VERSUS NPH INSULIN IN PRE PATIENTS

甘精胰岛素 (来得时) 与 NPH 胰岛素在术前患者中的比较

• 批准号: 7376125
• 负责人: Stephen colgan Clement
• 金额: $ 0.59万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376125
• 关键词: INSULIN; GLARGINE; LANTUS; VERSUS; NPH

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Most patients with insulin dependent diabetes require a long-acting insulin and a short-acting insulin with meals. High blood sugars can decrease the body's ability to respond to an acute illness. Various studies have shown that good blood sugar control while in the hospital can decrease the rate of complications and death. It is currently not known which long-acting insulin best controls blood glucose levels in hospitalized diabetic patients. We shall be comparing two types of long acting insulin: Lantus and NPH, in patients with diabetes undergoing surgery. We are investigating whether one type of insulin is better than another in controlling blood glucose levels. About one hundred people will take part in this study. Once they are admitted, the patients shall be assigned to one of 2 research treatment groups - to receive either NPH insulin or Lantus insulin as their long acting insulin. Both of these types of insulin are approved by the Food and Drug Administration (FDA) for clinical use and are not experimental medications. All subjects will receive Humalog insulin as the short acting insulin with meals. Insulin dosage will be calculated based on weight. A research nurse will administer the insulin. We shall monitor blood glucose levels by fingersticks every four hours. The times blood glucose levels shall be tested are 6 AM, 10 AM, 2 PM, 6 PM, 8 PM, 10 PM and 2AM. The insulin dosage shall be altered based on these levels. The Endocrinology Doctors-Dr Clement and Dr Bowen-Wright will do all insulin calculations. The study shall last for a minimum of three days and a maximum of five days. If the patients' are still in hospital after this time, the endocrinology consult team will manage their diabetes.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。大多数胰岛素依赖型糖尿病患者需要在进餐时使用长效胰岛素和短效胰岛素。高血糖会降低身体对急性疾病的反应能力。各种研究表明，住院期间良好的血糖控制可以降低并发症和死亡率。目前尚不清楚哪种长效胰岛素最能控制住院糖尿病患者的血糖水平。我们将在接受手术的糖尿病患者中比较两种类型的长效胰岛素：来得时和NPH。我们正在研究一种胰岛素在控制血糖水平方面是否比另一种更好。大约有100人将参加这项研究。一旦患者入院，应将其分配至2个研究治疗组之一-接受NPH胰岛素或来得时胰岛素作为长效胰岛素。这两种类型的胰岛素都是由食品和药物管理局（FDA）批准用于临床使用的，而不是实验性药物。所有受试者都将随餐接受Humanoid胰岛素作为短效胰岛素。胰岛素剂量将根据体重计算。一名研究护士将管理胰岛素。我们将每四小时用手指针刺监测血糖水平。血糖水平测试时间为上午6点、上午10点、下午2点、下午6点、下午8点、下午10点和上午2点。胰岛素剂量应根据这些水平进行调整。内分泌科医生Clement博士和Bowen-Wright博士将进行所有胰岛素计算。研究将持续至少三天，最多五天。如果患者在此时间后仍在住院，内分泌咨询团队将管理他们的糖尿病。